… and difficult-to-treat malignancies. From pioneering … accelerating its clinical development for treatment of adult patients … ’s potential in treating an aggressive subset … treatment of patients with gastrointestinal stromal tumors (GIST). On January 27, the FDA …

… to be developed for the treatment of … the management of gastrointestinal stromal tumors. Nature Clinical Practice … Future Market Insights. Gastrointestinal Stromal Tumor (GIST) Therapeutics Market … About Biodexa Pharmaceuticals PLC Biodexa Pharmaceuticals PLC …

… the treatment of patients with gastrointestinal stromal tumors ( … treatment options for nearly 2 decades. Recently, the FDA accepted a new drug … The developer reported … trial of CGT9486+sunitinib vs. sunitinib in subjects with gastrointestinal stromal tumors …

… company focused on developing precision therapies for genetically … S. Food and Drug Administration (FDA) has granted Breakthrough … with Gastrointestinal Stromal Tumors (GIST) who have received prior treatment with … from the PEAK trial which demonstrated a …

… drug application (NDA) for bezuclastinib plus sunitinib (Sutent) as treatment … for patients with gastrointestinal stromal tumors who have … the developer, Cogent Biosciences.1 The FDA’ … phase 3 trial in gastrointestinal stromal tumors (GIST). News …

… of innovative oncology drugs for orphan and … for the treatment of Chronic Myeloid Leukemia, Gastrointestinal Stromal Tumors (GISTs), … FDA at 1-800-FDA-1088 orwww.fda.gov/medwatch. DRUG … AMERICA INDUSTRY KEYWORD: FDA PHARMACEUTICAL HEALTH ONCOLOGY SOURCE: …

… S. Food and Drug Administration (FDA) has granted breakthrough … sunitinib) for patients with gastrointestinal stromal tumors (GIST) whose disease has … with the FDA and can speed the development and … used treatment after Gleevec progression. In the PEAK trial, …

… Sutent) for the treatment of patients with gastrointestinal stromal tumors (GIST), according … Evidence from the PEAK Trial The FDA's decision … expedite the development and review of drugs for serious … to complete its new drug application submission for …

… the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation … with Gastrointestinal Stromal Tumors (GIST). The trial included patients who received prior treatment with … combo regimen New Drug Application (NDA) under the FDA’s Real- …

… -label pharmacokinetic (PK) cohort of its ongoing CLEER-001 trial evaluating … a broad and consistent treatment effect across multiple clinically relevant … gastrointestinal stromal tumors (GIST) and systemic mastocytosis as early as 24 hours post-treatment …